"[I]t’s time to recognize that a different branding is needed along with a new senior leadership team with a strong track record of drug development . . ."
What a ridiculous statement, starting with the need to replace Missling for someone with a better record of drug development. Missling has done a flawless job to date of developing 2-73 with multiple successful trials and no setbacks. He has a clear strategic plan to expand the potential of 2-73 trials into a full CNS platform pharmaceutical. And how have the more senior leadership of Biogen, Lilly, Cortexyme et al done in the CNS space? Like everyone else but Missling, they have flamed out. And Missling's done it on the cheap, avoiding dilution. The guy is a star at drug development.
As for branding, others have pointed out the silliness of that remark.
News 
Market Data 
Discover 
